October 31, 2025

Intellia Therapeutics, Inc. (NTLA): Investor Outlook on a Potential 156.64% Upside in Gene Editing Innovations

Intellia Therapeutics, Inc. (NTLA), a trailblazer in the biotechnology sector, is capturing investor attention with its innovative approach to genome editing. Headquartered in Cambridge, Massachusetts, this clinical-stage company is at..

SI-BONE, Inc. (SIBN) Investor Outlook: With a 63.55% Potential Upside, What Lies Ahead?

SI-BONE, Inc. (NASDAQ: SIBN), a leader in the medical devices industry, is catching the eye of investors with a compelling potential upside of 63.55%. This healthcare sector player, headquartered in..

Celcuity Inc. (CELC) Stock Analysis: Unraveling a 4.48% Potential Upside in the Healthcare Biotech Sphere

Celcuity Inc. (CELC), a trailblazer in the biotechnology sector, is making waves with its innovative approach to targeted cancer therapies. Based in Minneapolis, Minnesota, this clinical-stage biotech company is dedicated..

ATAI Life Sciences N.V. (ATAI) Stock Analysis: Unveiling a 109.53% Potential Upside in Biotech Innovation

ATAI Life Sciences N.V. (NASDAQ: ATAI), a prominent player in the biotechnology sector, is making waves with its innovative approach to mental health treatment. Based in the Netherlands, this clinical-stage..

Sana Biotechnology, Inc. (SANA) Stock Analysis: A Promising 66% Upside in the Cell Therapy Market

Sana Biotechnology, Inc. (NASDAQ: SANA) is generating buzz among investors with its robust potential for growth in the biotechnology sector, particularly in the field of engineered cell therapies. With a..

Kamada Ltd. (KMDA) Stock Analysis: Exploring a Potential 105% Upside in the Healthcare Sector

Kamada Ltd. (NASDAQ: KMDA), a prominent player in the healthcare sector, is capturing investor attention with its robust pipeline of plasma-derived protein therapeutics and an impressive potential upside of over..

Surmodics, Inc. (SRDX) Stock Analysis: Navigating a Challenging Yet Promising Healthcare Landscape

Surmodics, Inc. (NASDAQ: SRDX), a key player in the healthcare sector specializing in medical devices, presents a complex yet intriguing scenario for investors. With its headquarters in Eden Prairie, Minnesota,..

SIGA Technologies Inc. (SIGA) Stock Analysis: Uncovering the Growth Potential Behind a 271.90% Revenue Surge

SIGA Technologies Inc. (NASDAQ: SIGA), a prominent player in the healthcare sector, specializes in the manufacturing of specialty and generic drugs. With a current market capitalization of $595.05 million, SIGA..

Auna SA (AUNA) Stock Analysis: Unpacking the 108.69% Potential Upside

Auna SA (AUNA), a Luxembourg-based healthcare giant, is garnering attention from investors with an enticing potential upside of 108.69%. Operating hospitals and clinics across Mexico, Peru, and Colombia, and offering..

Bicara Therapeutics Inc. (BCAX) Stock Analysis: Unveiling a Potential 95% Upside in the Biotech Sector

Bicara Therapeutics Inc. (NASDAQ: BCAX) is garnering significant attention from investors within the biotech sector, thanks to a remarkable potential upside of 95.28%. This clinical-stage biopharmaceutical company, headquartered in Boston,..

Embecta Corp. (EMBC) Stock Analysis: Is a 22% Upside Within Reach?

Embecta Corp. (NASDAQ: EMBC) is garnering attention in the healthcare sector, particularly from investors seeking opportunities in medical instruments and supplies. With a market cap of $798.91 million, this United..

Sonida Senior Living, Inc. (SNDA) Stock Analysis: Navigating Challenges with a 1.84% Potential Upside

Sonida Senior Living, Inc. (SNDA), a key player in the healthcare sector, specifically in the medical care facilities industry, has been a focal point for investors seeking opportunities in the..

Treace Medical Concepts, Inc. (TMCI) Stock Analysis: Exploring a 32.55% Potential Upside in the Medical Devices Sector

Treace Medical Concepts, Inc. (NASDAQ: TMCI) operates in the healthcare sector, specifically within the medical devices industry, and is garnering attention due to its innovative solutions for bunion correction and..

Prothena Corporation plc (PRTA) Stock Analysis: Exploring a 57% Potential Upside Amidst Biotech Sector Challenges

Prothena Corporation plc (NASDAQ: PRTA), a biotechnology firm headquartered in Dublin, Ireland, operates at the frontier of healthcare innovation, focusing on the development of novel therapies for diseases caused by..

REGENXBIO Inc. (RGNX) Stock Analysis: Unpacking a 128% Potential Upside with Strong Buy Ratings

For investors with a keen eye on the biotechnology sector, REGENXBIO Inc. (NASDAQ: RGNX) presents an intriguing opportunity, underscored by a significant potential upside of 128.34%. This clinical-stage biotech company,..

Arbutus Biopharma Corporation (ABUS) Stock Analysis: A High-Potential Biotech with 522% Revenue Growth

Arbutus Biopharma Corporation (NASDAQ: ABUS) presents a compelling opportunity for investors looking to tap into the high-growth potential of the biotechnology sector. With a market capitalization of $927.82 million and..

Replimune Group, Inc. (REPL) Stock Analysis: Eyeing a 3.66% Upside in the Biotech Sector

Replimune Group, Inc. (NASDAQ: REPL) has been catching the attention of investors with its promising oncolytic immunotherapies targeting cancer treatment. As a clinical-stage biotechnology company headquartered in Woburn, Massachusetts, Replimune..

AbCellera Biologics Inc. (ABCL) Stock Analysis: Exploring a Potential 74% Upside

AbCellera Biologics Inc. (ABCL), a prominent player in the biotechnology sector, is making waves with its innovative approach to antibody-based medicine. Headquartered in Vancouver, Canada, the company is renowned for..

KalVista Pharmaceuticals, Inc. (KALV) Stock Analysis: A Biotech Play with 180% Potential Upside

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a burgeoning player in the biotechnology sector, presents an intriguing opportunity for investors with a risk appetite and a keen eye on the healthcare market...

Dianthus Therapeutics, Inc. (DNTH) Rating Update: Analyst Consensus Suggests 84.15% Upside

Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a promising player in the biotechnology sector, is attracting investor attention with a market capitalization of $1.34 billion. This clinical-stage company, headquartered in New York,..

Search

Funds

October 31, 2025

Search

Funds

October 31, 2025

FTSE 100

Funds